With evolving diagnostic criteria and the advent of new oral and parenteral therapies for MS,
most current diagnostic and treatment algorithms need revision and updating. The diagnosis …

Despite the availability of a lot of effective disease-modifying drugs, multiple sclerosis
(MS)(in particular the progressive forms) still represents an important unmet medical need …

Background High-efficacy therapies in multiple sclerosis are traditionally used after
unsuccessful treatment with first-line disease modifying therapies. We hypothesised that …

Importance Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B
cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared …

Microglia are prominent immune cells in the central nervous system (CNS) and are critical
players in both neurological development and homeostasis, and in neurological diseases …

Background With ocrelizumab another drug is available for the treatment of multiple
sclerosis (MS). Little is known on the long-term use of ocrelizumab on immune cell subsets …

Rituximab, a chimeric anti-CD20-antibody, attracts increasing attention as a treatment option
for multiple sclerosis (MS). Apart from smaller controlled trials, an increasing number of …

Background Rituximab is safe and effective for treating relapsing–remitting multiple sclerosis
(RRMS) according to phase II and observational studies. There are limited data on disease …

Objective. To evaluate the efficacy and safety of rituximab in multiple sclerosis in a clinical
practice setting. Methods. Clinical data for all adult patients with multiple sclerosis (MS) …

Background Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS).
More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo …